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Background. Chronic diarrhoea is a common, but
poorly investigated diabetes complication. Auto-
nomic neuropathy is a leading pathophysiological
theory founded on old, small studies. Studies of
gastrointestinal motility and pH levels are lacking.
Objectives. Using new diagnostic methods, we aimed
to find out if diabetic diarrhoea was associated with
alterations in gastrointestinal motility, pH levels
and autonomic function.
Methods. Fifty-seven patients (42 women, 46 type 1
diabetes) were prospectively included. Symptoms
were evaluated with the gastrointestinal symp-
tom rating scale, defining ≥ 4 points as cases
with diarrhoea. Patients scoring < 4 were used
as controls. We used the wireless motility cap-
sule to measure gastrointestinal transit times,
pH levels and contractility parameters. Autonomic
function was assessed by measuring heart rate
variability, baroreflex sensitivity and orthostatic
hypotension.
Results. Seventeen patients (30%) had diarrhoea.
Compared with controls, cases had slower gas-
tric emptying (21:46 vs. 4:14, h:min, p = 0.03)
and faster colonic transit (18:37 vs. 54:25, p <
0.001). Cases had increased intraluminal pH in
the antrum (2.4 vs. 1.2, p = 0.009), caecum (7.3
vs. 6.4, p = 0.008) and entire colon (7.1 vs. 6.7,
p = 0.05). They also had a decreased pH differ-
ence across the pylorus (3.3 vs. 4.9, p = 0.004)
and ileocaecal junction (0.6 vs 1.0, p = 0.009). The
groups did not differ in autonomic function, but
diastolic blood pressure drop correlated rs = −0.34
(p = 0.04) with colonic transit time.
Conclusions. Patients with diabetic diarrhoea had
altered gastrointestinal transit and intraluminal
pH levels, but minimal changes in autonomic func-
tion. Our results suggest that tests of gastrointesti-
nal function are clinically useful in diabetic diar-
rhoea.
Keywords: autonomic dysfunction; diabetic diar-
rhoea; diabetic gastroenteropathy; gastrointestinal
transit; intraluminal pH levels; wireless motility
capsule
Abbreviation: GSRS, Gastrointestinal Symptom Rat-
ing Scale
Introduction
Chronic diarrhoea affects more than 10% of dia-
betes patients and often leads to impaired qual-
ity of life [1,2]. Evaluation can be challenging, as
diabetes patients are at increased risk for devel-
oping other conditions leading to diarrhoea, like
coeliac disease, pancreatic exocrine insufficiency
and inflammatory bowel disease [3–7]. Diarrhoea
may also come from dietary factors or common
antidiabetic drugs like metformin and glucagon-
like peptide-1 agonists [8–11]. However, in half
of all patients, the diarrhoea will be attributed to
alterations in intestinal motility and secretion sec-
ondary to diabetic gastroenteropathy [12]. Diabetic
gastroenteropathy can affect any portion of the gas-
trointestinal tract, leading to manifestations like
oesophageal dysmotility, gastroparesis and intesti-
nal hyper- or hypomotility [11,13,14]. When these
patients present with chronic diarrhoea, it has
been termed diabetic diarrhoea [12]. Here, the
diarrhoea is typically nonbloody and painless, with
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a high-volume, watery consistence. It may be noc-
turnal and can lead to faecal incontinence [1,12].
Although being recognized for almost a century,
little is known about the pathophysiological mech-
anisms behind diabetic diarrhoea [13]. The leading
theory of autonomic neuropathy was established
after finding high covariance between neuropa-
thy and diarrhoea in case studies and a clinical
resemblance with patients who had undergone
vagotomy or sympathectomy [15,16]. Later studies
are limited in numbers, inconclusive, and there
are no studies using new technology for assessing
autonomic function [13,15,17–19]. Studies inves-
tigating intestinal transit and contractility are also
lacking. One explanation may be that these mea-
surements previously have been laborious and
patient unfriendly, limiting their availability to
specialized centres. Recently, the wireless motility
capsule has emerged as a promising method,
simultaneously measuring transit times and con-
tractility throughout the gastrointestinal tract
whilst patients are ambulant [20]. The capsule
also measures pH levels [21]. This is relevant
since diarrhoeal disorders are associated with
both intraluminal and systemic pH level alter-
ations [22,23]. So far, these measurements are
unexplored in diabetic diarrhoea, but there are
noteworthy findings from studies on patients with
irritable bowel syndrome and small intestinal
bacterial overgrowth [24,25].
In this study, our main hypothesis was that dia-
betes patients with diarrhoea had altered gastroin-
testinal transit times. We also hypothesized that
they had altered intraluminal pH levels, reduced
contractility and autonomic dysfunction. To inves-
tigate this, we examined a cohort of diabetes
patients with gastrointestinal symptoms and sus-
pected gastroenteropathy using wireless motility
capsule and autonomic function tests.
Methods
Study population
Between 2014 and 2018, we prospectively included
diabetes patients with symptoms suggestive of
gastroenteropathy into a cross-sectional, obser-
vational study. All patients had been referred
for diagnostic evaluation at a tertiary centre at
Haukeland University Hospital, Bergen, Norway.
Inclusion criteria were type 1 or type 2 diabetes,
age over 18 years and normal upper endoscopy.
Exclusion criteria were pregnancy, breastfeeding,
active malignancy (defined as any cancer not in
complete remission for the last six months) and
lack of ability to comply with the study protocol.
Patients were admitted to the hospital during the
study, where they were interviewed and examined
by a physician, and delivered blood, urinary and
faecal samples (Table 1). They were kept on intra-
venous glucose-insulin infusion during fasting and
examinations, with a target glucose level between
4 and 10 mmol/L.
Wireless motility capsule
The wireless motility capsule (SmartPill;
Medtronic, Minneapolis, USA) is a 26 × 13 mm
indigestible, single-use capsule. It registers tem-
perature (range 25–49°C), pH (0.5–9.0) and pres-
sure (0–350 mmHg) throughout the gastrointesti-
nal tract. During the test, data are transferred to a
portable data receiver and afterwards downloaded
to a computer. For analysis, we used MotiliGI®
software version 3.0 (Medtronic).
We used stereotypical pH profiles to define transit
times [21]: Gastric emptying time (capsule inges-
tion – pylorus), small bowel transit time (pylorus
– ileocaecal junction), colonic transit time (ileocae-
cal junction – capsule expulsion); and whole gut
transit time (capsule ingestion – capsule expul-
sion). Antral pH was defined as median pH for
the last 15 min before the pylorus; duodenal pH
the first 15 min after the pylorus; ileum the last
15 min before the ileocaecal junction; caecum the
first 15 min after the ileocaecal junction; and rec-
tum the last 15min before capsule expulsion. Delta
pylorus was defined as the difference between duo-
denal and antral pH; delta ileocaecal junction the
difference between ileal and caecal pH.
We also measured the motility index and contrac-
tions per minute in the whole stomach, small bowel
and colon [20]. To determine the ileocaecal junction
pressure, we used the method proposed by Chan-
der Roland et al., identifying the maximum pres-
sure for the last 4 min prior to the ileocaecal junc-
tion pH drop [25].
All patients had to pause medications potentially
altering intestinal function before and during the
study. We have specified details in a previous arti-
cle, together with a description of the test meal and
initiation protocol [26]. Patients continued other
regular medications, provided doses had been
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stable for 3 months. Intake of alcohol was prohib-
ited, and patients were asked to refrain from smok-
ing and strenuous physical activity.
Autonomic function tests
We assessed heart rate variability at rest and
baroreflex sensitivity using the Heart Rhythm
Scanner PE and the Biocom 5000 Bluetooth ECG
Recorder (Biocom Technologies, Poulsbo, USA). We
have described the heart rate variability protocol in
a previous paper [27]. To measure baroreflex sen-
sitivity, patients took deep breaths at a rate of five
per minute. Thereafter, actual values were com-
pared with predicted normative age-adjusted val-
ues by the software. Finally, we assessed ortho-
static hypotension using Welch Allyn ProBP 3400
(Welch Allyn Inc., Skaneateles Falls, USA) following
a standardized protocol measuring supine, resting
blood pressure and standing blood pressure after 1
and 3 min. Orthostatic hypotension was defined as
a drop in systolic blood pressure of ≥20 mm Hg or
diastolic blood pressure ≥10 mm Hg from supine
to standing position [28].
Symptom assessments
Symptoms were evaluated by physician interview
and using the Gastrointestinal Symptom Rating
Scale (GSRS), a questionnaire validated for assess-
ing the occurrence and severity of upper and lower
gastrointestinal symptoms during the last week
[29]. GSRS includes 15 questions, each rated from
no discomfort (zero points) to very severe discom-
fort (six points). Diarrhoea syndrome (hereafter
named ‘diarrhoea’) is derived by taking the mean
of the individual symptoms: increased passage of
stools, loose stools and urgent need for defecation
[29]. We used a cut-off value of ≥4 points, corre-
sponding to the 75th percentile, to define cases
with diarrhoea. Those scoring<4 were used as con-
trols. We also looked at correlations between diar-
rhoea score and each wireless motility capsule and
autonomic function test parameter.
Statistical analysis
Continuous variables are stated as median (quar-
tiles) and categorical variables as n (%). We used
the Mann–Whitney U test to compare two continu-
ous variables, using r as an effect size estimate (r
= z/square root of the total number of cases, N).
To examine associations between continuous vari-
ables, we used Spearman’s Rank Order Correlation
test (rs) with bootstrapped 95% confidence inter-
vals (CI) and the coefficient of determination (R2
= rs squared). We used Pearson’s chi-square test
to compare categorical variables with Cramér’s V
(ɸc) as an effect size estimate. Agreement was eval-
uated using Cohen’s kappa measure of agreement
(κ). Statistical significance was defined as p ≤ 0.05.
Analyses were performed using IBM SPSS Statis-
tics (Version 27, IBM Corporation, USA), except
effect size estimates for the Mann–Whitney U test
and R2, which were calculated using Microsoft
Excel (Version 2102, Microsoft Corporation, USA).
For both r and ɸc, effect sizes can be interpreted
using Cohen’s criteria (1988): Small effect (>0.10),
medium effect (>0.30) and large effect (>0.50) [30].
Ethical considerations
All participants submitted oral and written consent
prior to study-related procedures. The study was
approved by The Western Norway Regional Medi-
cal Ethics Committee (2015/58) and conducted in
accordance with the Declaration of Helsinki.
Results
Seventy-two patients were included in the study, of
which 68 were examined with wireless motility cap-
sule. We were unable to identify the ileocaecal junc-
tion in three patients, precluding determination of
small bowel and colonic transit. Of the remaining
65 patients, eight had missing GSRS data, leaving
57 available for comparisons. An inclusion flow-
chart is shown in Fig. 1.
Clinical characteristics
Clinical characteristics are presented in Table 1.
Fifty patients (88%) used insulin, three (5%)
sodium-glucose cotransporter-2 inhibitors, two
(4%) glucagon-like peptide-1 agonists, two (4%)
dipeptidyl peptidase-4 inhibitors and one (2%)
used pioglitazone. Four patients (7%) used
antidiarrhoeal medications. A detailed list of
medications are provided in Table S1.
We identified 17 (30%) cases with a diarrhoea score
≥4 points, compared to 12 (21%) reporting diar-
rhoea during physician interview, κ = 0.68, p <
0.001. Median score in all patients were 2.7 (0.5–
4.0), with no difference between women (2.3, 0.6–
4.0) and men (2.7, 0–5.0, p = 0.81, r = 0.03), nor
between type 1 diabetes (2.8, 0.7–4.1) and type 2
diabetes (2.0, 0–4.0, p = 0.46, r = 0.10). Those with
one or more late diabetes complications scored
3.0 (0.8–4.3), those without 0.7 (0–3.5), p = 0.06,
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FIGURE 1 Inclusion flow chart.
r = 0.25. Cases and controls did not differ in age,
BMI, diabetes duration, HbA1c, faecal elastase-1,
nor faecal calprotectin levels.
Transit times, pH levels and contractility parameters
A comparison of transit times, pH levels and con-
tractility parameters between cases and controls
are presented in Table 2. Transit times are also
displayed in Fig. 2, pH levels in Fig. 3. Correla-
tions between all wireless motility capsule mea-
surements and the continuous GSRS diarrhoea
score are shown in Table S2.
We found that cases had slower gastric emptying
(p = 0.03) and faster colonic transit (p < 0.001)
than controls. We found no difference in small
bowel transit (p = 0.11) nor whole gut transit (p =
0.16). Colonic transit correlated with the diarrhoea
score, p = 0.006.
We found that cases had increased antral pH
(p = 0.009) and decreased pH difference across
the pylorus (p = 0.004). Cases also had increased
colonic pH (p = 0.05), increased caecal pH (p =
0.008) and decreased pH difference across the ileo-
caecal junction (p = 0.009). Antral pH (p = 0.02),
ileal pH (p = 0.03), caecal pH (p = 0.006) and pH
differences across the pylorus (p = 0.001) and ileo-
caecal junction (p = 0.04) all correlated with diar-
rhoea scores.
We found no correlations between transit times
and pH in the stomach (rs = 0.02, 95% CI −0.24–
0.28, R2 = 0.0%, p = 0.86), small bowel (rs = 0.10,
95%CI−0.16–0.34, R2 = 1.0%, p= 0.46), nor colon
(rs = −0.14, 95% CI −0.37–0.12, R2 = 2.0%, p =
0.32). There was no correlation between pH dif-
ference across the ileocaecal junction and colonic
transit time, rs = 0.13, 95% CI −0.12–0.38, R2 =
1.7%, p = 0.34.
We found no difference between cases and controls
in any of the contractility parameters, all p > 0.23.
Neither did we identify any significant correlations
with the GSRS diarrhoea score, all p > 0.35.
Autonomic function tests
In Table 3, we present a comparison of auto-
nomic function tests between cases and controls,
as defined by the GSRS cut-off value. Correlations
between autonomic function test parameters and
the GSRS diarrhoea score are shown in Table S3.
In cases, we found a trend towards increased dias-
tolic blood pressure drop at 3 min, p = 0.054. We
found no difference in any of the other parameters
(all p > 0.10) and no significant correlations (all p
> 0.10). Thirteen controls (33%) and eight cases
(57%) had orthostatic hypotension, χ2 (1) = 2.65,
p = 0.10, ɸc = 0.22. Of all autonomic function test
parameters, only diastolic blood pressure drop at 0
min correlated significantly (p = 0.04) with colonic
transit time, Table S4.
Discussion
In this study we aimed to investigate the associ-
ation between diabetic diarrhoea, intestinal motil-
ity, pH levels and autonomic dysfunction. By exam-
ining diabetes patients with wireless motility cap-
sule, we found that patients with diarrhoea had
slower gastric emptying and faster colonic transit
than controls. They also had an increased pH level
in the stomach’s antrum, caecum and entire colon
and decreased pH difference across the pylorus
and ileocaecal junction. We found a moderate neg-
ative correlation between diastolic blood pressure
drop and colonic transit time, but no other associ-
ations between diabetic diarrhoea and autonomic
dysfunction.
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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TABLE 2. Wireless motility capsule measurements of transit times, pH levels and contractility parameters: a comparison of
diabetes patients with diarrhoea and controls
Variables/location, unit Controls Cases p value Effect size
Transit times
Stomach, h:min 4:14 (3:11–19:26) 21:46 (3:58–47:12) 0.03 0.29
Small bowel, h:min 4:44 (3:51–6:03) 3:36 (2:24–6:52) 0.11 0.21
Colon, h:min 54:25 (22:56–78:11) 18:37 (7:23–35:08) <0.001 0.49
Whole gut, h:min 72:44 (38:11–105:32) 57:05 (31:59–74:07) 0.16 0.19
pH levels
Stomach (whole) 1.6 (1.1–2.8) 1.6 (1.4–3.6) 0.45 0.10
Antrum 1.2 (0.8–1.8) 2.4 (1.5–2.9) 0.009 0.35
Delta pylorus 4.9 (3.6–5.4) 3.3 (2.3–4.4) 0.004 0.38
Small bowel (whole) 7.4 (7.0–7.6) 7.1 (6.6–7.7) 0.35 0.12
Duodenum 6.2 (5.6–6.6) 5.9 (4.8–6.5) 0.25 0.15
Ileum 7.7 (7.3–7.8) 7.8 (7.4–8.4) 0.19 0.17
Delta ICJ 1.0 (0.7–1.5) 0.6 (0.3–0.9) 0.009 0.35
Colon (whole) 6.7 (6.2–7.0) 7.1 (6.7–7.3) 0.05 0.26
Caecum 6.4 (5.9–6.9) 7.3 (6.7–7.7) 0.008 0.35
Rectum 7.5 (7.0–7.9) 7.4 (6.4–7.8) 0.23 0.16
Contractility parameters
Gastric MI, mmHg·s/min 40.2 (27.0–65.2) 42.6 (32.8–75.0) 0.61 0.07
Gastric Ct, number/min 1.1 (0.8–1.7) 1.2 (0.8–2.0) 0.58 0.07
Small bowel MI, mmHg·s/min 136.0 (84.5–226.1) 182.7 (106.4–266.6) 0.23 0.16
Small bowel Ct, number/min 3.9 (2.3–5.2) 4.1 (2.8–6.3) 0.38 0.12
ICJ pressure, mmHg·s/min 40.6 (25.1–62.9) 39.0 (23.9–75.8) 0.62 0.07
Colonic MI, mmHg·s/min 148.6 (104.8–254.3) 132.7 (88.5–259.8) 0.77 0.04
Colonic Ct, number/min 1.3 (1.1–2.0) 1.7 (1.0–2.7) 0.50 0.09
Results are presented as median (quartiles). Cases are defined by GSRS diarrhoea score ≥4 points; controls <4. Transit
times, pH variables and contractility parameters are defined in the Methods section.
Abbreviations: Ct, Contractions; GSRS, Gastrointestinal Symptom Rating Scale; ICJ, Ileocaecal junction; MI, Motility
index.
FIGURE 2 Box-plots showing regional transit times in controls and cases. Statistical significance of p ≤ 0.05 are marked
by *; p < 0.01 are marked by **. Results are given as median (quartiles). Transit times (hours: minutes): (a) Stomach: 4:14
(3:11–19:26) in controls versus 21:46 (3:58-47:12) in cases, p = 0.03; (b) Small bowel: 4:44 (3:51–6:03) versus 3:36 (2:24-
6:52), p = 0.11; (c) Colon: 54:25 (22:56–78:11) versus 18:37 (7:23–35:08), p < 0.001; Whole gut: 72:44 (38:11–105:32)
versus 57:05 (31:59–74:07), p = 0.16.
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FIGURE 3 Box-plots showing regional pH levels in controls and cases. Statistical significance of p ≤ 0.05 are marked by *;
p < 0.01 are marked by **. Results are given as median (quartiles). Stomach pH levels: (a) Stomach (whole): 1.6 (1.1–2.8) in
controls versus 1.6 (1.4–3.6) in cases, p = 0.45; (b) Antrum: 1.2 (0.8–1.8) versus 2.4 (1.5–2.9), p = 0.009; (c) Delta pylorus:
4.9 (3.6–5.4) versus 3.3 (2.3–4.4), p = 0.004. Small bowel pH levels: (d) Small bowel (whole): 7.4 (7.0–7.6) versus 7.1 (6.6–
7.7), p = 0.35; (e) Duodenum: 6.2 (5.6–6.6) versus 5.9 (4.8–6.5), p = 0.25; (f) Ileum: 7.7 (7.3–7.8) versus 7.8 (7.4–8.4), p =
0.19; (g) Delta ICJ: 1.0 (0.7–1.5) versus 0.6 (0.3–0.9), p = 0.009. Colonic pH levels: (h) Colon (whole): 6.7 (6.2–7.0) versus
7.1 (6.7–7.3), p = 0.05; (i) Caecum 6.4 (5.9–6.9) versus 7.3 (6.7–7.7), p = 0.008; (j) Rectum 7.5 (7.0–7.9) versus 7.4 (6.4–7.8),
p = 0.23. Abbreviation: ICJ = Ileocaecal junction.
Previous studies of intestinal dysmotility in dia-
betic diarrhoea have shown divergent results [31–
36]. Some have found an association between dia-
betic diarrhoea, prolonged transit time and small
intestinal bacterial overgrowth [31,33,34]. Others
have found results similar to ours, with shortened
intestinal transit, some also identifying a corre-
lation with autonomic dysfunction [12,32,35,36].
Theoretically, autonomic dysfunction may induce
intestinal dysmotility through several pathways.
Loss of inhibitory input through damaged sym-
pathetic innervation could explain the rapid tran-
sit seen in our diarrhoea patients [17]. Stimula-
tion of alpha-adrenergic receptors on enterocytes
is also important for intestinal fluid absorption,
and autonomic dysfunction could lead to increased
colonic fluid levels and watery diarrhoea [1,13].
Alterations in the sympathetic and parasympa-
thetic nervous systems have been found in several
human pathological studies [17,37]. Despite this,
Whalen and colleagues demonstrated intact effer-
ent autonomic function in patients with diabetic
diarrhoea when investigating intestinal motility in
response to intravenous stimulation by adrenergic
and cholinergic agents [38]. They did, however, find
reduced pain response to intrajejunal balloon dis-
tention, indicating afferent dysfunction [38]. Sim-
ilar findings have been made in the oesophagus,
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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TABLE 3. Autonomic function tests: a comparison of diabetes patients with diarrhoea and controls
Variable, unit Controls Cases p value Effect size
Heart rate variability (time-domain measures)
Mean heart rate, bpm 74.1 (66.8–86.3) 71.3 (64.2–84.4) 0.63 0.07
Mean NN 802.8 (689.9–939.6) 841.4 (745.7–948.5) 0.51 0.11
SDNN, ms 24.6 (12.7–35.0) 20.1 (15.0–30.7) 0.70 0.06
RMSSD, ms 15.8 (6.9–26.9) 14.0 (11.7–21.1) 0.64 0.07
Heart rate variability (frequency-domain measures)
Total power, ms2 67.8 (21.2–272.8) 80.0 (5.1–219.1) 0.59 0.08
Very low frequency, ms2 54.1 (19.5–132.3) 60.6 (13.8–129.1) 1.00 0.00
Low frequency, ms2 26.5 (4.9–54.7) 30.0 (4.3–68.5) 0.84 0.03
High frequency, ms2 10.6 (4.1–48.8) 14.3 (3.4–34.2) 0.92 0.02
LF norm, nu 58.6 (39.1–78.6) 62.8 (45.1–74.2) 0.69 0.06
HF norm, nu 41.4 (21.4–61.0) 37.2 (25.9–54.9) 0.69 0.06
LF/HF ratio 1.4 (0.7–3.7) 1.7 (0.8–3.0) 0.66 0.07
Baroreflex sensitivity
Standard deviation of HR 3.3 (2.2–5.1) 4.2 (2.2–4.4) 0.92 0.02
Maximal variance of HR 11.0 (5.2–16.0) 6.9 (5.0–11.3) 0.28 0.16
Mean variance of HR 6.8 (3.0–11.5) 4.8 (3.2–8.1) 0.52 0.09
E/I ratio 1.09 (1.03–1.18) 1.07 (1.04–1.14) 0.74 0.05
Orthostatic tests
30:15 ratio 1.06 (1.03–1.19) 1.06 (1.03–1.11) 0.47 0.11
Resting systolic BP 122 (112–134) 126 (115–138) 0.16 0.19
Resting diastolic BP 75 (66–82) 77 (65–84) 0.64 0.06
Systolic BP drop at 0 min 3 (-3–15) 25 (-1–31) 0.32 0.17
Diastolic BP drop at 0 min 3 (-4–8) 10 (2–16) 0.10 0.27
Systolic BP drop at 1 min 2 (-4–18) 3 (-8–21) 0.97 0.01
Diastolic BP drop at 1 min 1 (-6–6) 2 (-6–11) 0.55 0.08
Systolic BP drop at 3 min 2 (-4–12) 9 (1–27) 0.10 0.22
Diastolic BP drop at 3 min -1 (-7–6) 4 (-1–18) 0.054 0.26
Results are presented as median (quartiles). Cases are defined by GSRS diarrhoea score ≥4 points; controls <4.
Abbreviations: BP, Blood Pressure; Bpm, Beats per minute; E/I ratio, Expiration/Inspiration ratio; GSRS, Gastroin-
testinal Symptom Rating Scale; HF norm, nu, High frequency normalized units; HR, Heart Rate; LF/HF ratio, low-
frequency/high-frequency ratio; LF norm, nu, Low frequency normalized units; RMSSD, Root mean square of successive
RR interval differences; SDNN, Standard deviation of NN intervals (inter-beat intervals where artefacts are removed).
duodenum and rectum, whilst gastric barostat
studies have found the opposite in diabetic gas-
troparesis: visceral hypersensitivity [39–41]. Stud-
ies utilizing cardiac autonomic function tests in
patients with diabetic gastroenteropathy, have also
provided conflicting results [36,42,43].
In this study, we were unable to find any differ-
ences between cases and controls in heart rate
variability or baroreflex sensitivity. Neither did we
find any correlations between these parameters
and diarrhoea score. We did, however, find a trend
towards an increased orthostatic blood pressure
drop in cases. In addition, we found a moder-
ate negative correlation with colonic transit time.
These results could indicate a possible impairment
of the sympathetic nervous system, although in
such case, we would have expected to find differ-
ences in the high frequency spectres of the heart
rate variability as well [28,44]. Overall, our results
imply that other mechanisms than autonomic dys-
function are more prominent in the pathophysi-
ology of diabetic diarrhoea. One explanation for
our findings, could be that some patients in the
comparator group also had enteric dysmotility. All
patients had gastrointestinal symptoms and a clin-
ical suspicion of gastroenteropathy, but controls
differed with respect to not reporting diarrhoea. To
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investigate this further, we found that a small pro-
portion of controls had slow-transit constipation,
as defined by GSRS and prolonged colonic tran-
sit [21,29]. However, excluding these patients did
not alter the statistical significance of our original
results.
Another pathophysiological theory potentially
explaining our findings, is the loss of enteric
neurons [17]. Through the production of nitro-
gen monoxide, these neurons have an important
inhibitory effect on gastrointestinal peristalsis, and
their depletion may lead to accelerated transit [1].
Apoptosis of enteric glial cells may aggravate neu-
ronal loss [1]. Another possible mechanism may be
reduced synthesis of sodium hydrosulphide, which
acts as an inhibitor of intestinal smooth muscles
[45]. There are conflicting results regarding the role
of bile acid malabsorption in diabetic diarrhoea,
but the theory has recently gained new impetus
[12,46]. Increased levels of colonic bile acids might
explain diarrhoea through several mechanisms,
including a direct stimulatory effect on motility
[47]. Small intestinal carbohydrate malabsorp-
tion may accelerate colonic transit through an
increased fluid load, but short-chain fatty acids
produced by fermentation of carbohydrates, slow
down transit [48]. Additional mechanisms possibly
contributing to dysmotility are neuroendocrine
dysregulation, alterations of smooth muscle cells
and loss of interstitial cells of Cajal [17]. Interest-
ingly, the effect of hyperglycaemia is somewhat
paradoxical: whilst chronic hyperglycaemia is cen-
tral in the development of enteric neuropathy, and
hence leads to accelerated transit, acute hyper-
glycaemia leads to delayed transit throughout the
entire gastrointestinal tract [13,14,17].
Our study is the first to report intestinal pH alter-
ations in patients with diabetic diarrhoea. Previ-
ously, this has been investigated in asymptomatic
type 1 diabetes patients with peripheral neuropa-
thy, finding decreased colonic pH levels and an
increased pH difference across the ileocaecal junc-
tion compared to healthy controls [49,50]. Similar
findings have been demonstrated in irritable bowel
syndrome [24]. Normally, the pH level decreases
more than one unit across the ileocaecal junction
as a consequence of the more acidic environment
in the caecum compared to the ileum [21]. This is
mostly due to bacterial fermentation and produc-
tion of short-chain fatty acids [49]. The magnitude
of the ileocaecal pH drop has therefore been sug-
gested as a proxy for the degree of fermentation
in the proximal colon [51]. This may be increased
in carbohydrate malabsorption or with heightened
intake of fibre or other nonabsorbable sugars, the
latter being a common cause of diarrhoea in dia-
betes [8,11,48]. When our cases had a decreased
ileocaecal pH drop and an increased intracolonic
pH profile than controls, this may reflect another
microbial profile [21,49]. A number of factors may
influence microbial composition, including diet,
stool consistency, intestinal transit times and bile
acids [52,53]. Theoretically, bile acid malabsorp-
tion may lead to colonic pH alterations directly,
but this is so far not reported in studies. Differ-
ent types of nutrients can influence pH levels indi-
rectly, where increased production of ammonium
in high protein-diets may lead to an alkaline intra-
colonic milieu [52]. In contrast to fermentation of
carbohydrates, protein fermentation is most pro-
nounced in lower parts of the colon, thus being a
less likely cause of our caecal pH findings [53]. The
interrelationship between intestinal transit and pH
levels may be unpredictable: when colonic transit
is rapid, pH levels may increase as bacteria have
less time to ferment carbohydrates. At the same
time, rapid transit may induce a shift towards lac-
tate production, potentially lowering pH levels [52].
In this study, we found no association between pH
levels and transit times.
Another possible explanation for our findings of a
more alkaline caecal micromilieu may be altered
activation of receptors facilitating bicarbonate
secretion [54]. Interestingly, a study administering
linaclotide to patients with irritable bowel syn-
drome with constipation, increased caecal pH,
reduced colonic transit time and improved symp-
toms [51]. Linaclotide exerts its effect through
increased luminal secretion of chloride and bicar-
bonate, in next case leading to increased efflux
of water [51]. Ileocaecal valve dysfunction could
lead to a decreased pH drop across the ileocae-
cal junction, as shown in patients with Crohn’s
disease who had undergone ileocaecal resection.
Compared to controls, patients had increased pH
in the caecum, whilst ileal pH levels were similar
[55]. Ileocaecal valve dysfunction has also been
associated with bacterial overgrowth [25]. How-
ever, we did not find any differences in ileocaecal
junction pressure between cases and controls.
Neither did we find any other differences in con-
tractility parameters, but this should be explored
in more detail in future studies. New studies
are also needed to investigate the many potential
causes of pH level alterations in diabetic diarrhoea,
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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including characterization of the microbiome and
tests for bile acid malabsorption and bacterial
overgrowth.
Previous studies have shown that wireless motil-
ity capsule examinations have large therapeutic
consequences, providing new diagnoses in 50%
of patients and changing treatment in 75% [56].
Our results also suggest that tests of gastroin-
testinal motility and pH levels have a role in the
evaluation of diabetic diarrhoea, potentially guid-
ing medical treatment. As an example, the patient
with slow small bowel transit secondary to bac-
terial overgrowth, needs a different therapeutic
approach than the patient with rapid colonic tran-
sit caused by enteric neuropathy. Many diabetes
patients also have concurrent dysmotility in more
than one gastrointestinal segment, evidenced by
our diarrhoea patients having both delayed gas-
tric emptying and rapid colonic transit [12,35,56].
Here, motility testing may help to tailorize phar-
macological treatment [13,35,57,58]. Furthermore,
alterations in pH levels or changes in luminal water
content may affect intestinal drug delivery and
absorption, being especially relevant for the release
of active substances from drugs with controlled
release formulations [14]. Although not yet inves-
tigated in diabetes, intestinal pH level alterations
may also be linked to visceral sensitivity [59].
Finally, and crucially, the attention to this under-
reported and undertreated diabetes complication
should be increased in health care providers. It is
worrying that 30% of our study patients had diar-
rhoea, but only 7% used antidiarrhoeal medica-
tions.
There are some methodological considerations
regarding our study. We used a validated question-
naire to assess bowel function [29]. As there are
no predefined dichotomous cut-off values for the
GSRS diarrhoea syndrome, we chose to define ≥4
points as cases with diarrhoea. This cut-off value
was intentionally conservative, to maximize sensi-
tivity for detecting true diarrhoea cases. A post hoc
Kappa analysis, demonstrated a substantial agree-
ment between our chosen cut-off for diarrhoea
and clinical information gathered from physician
interviews. Additionally, we performed correlation
analyses showing similar results, thus strength-
ening our findings. Furthermore, exact localiza-
tion of the wireless motility capsule is only possi-
ble when it passes the pylorus, ileocaecal junction
or is expelled from the body [60]. The definition of
gastrointestinal subsegments is therefore based on
temporal measurements in relation to these physi-
ological landmarks. We utilized pH measurements
15 min before and after the pylorus and ileocaecal
junction to determine pH in the adjacent subseg-
ments, similar to the reference study by Wang and
colleagues [21]. Other studies have used 30-min
measurements or split the intestines into quar-
tiles [49,50,61]. Compared to these approaches,
15-min measurements are preferential in patients
with rapid transit. Due to the large variance in
transit times, it also has an advantage over the
quartile approach when it comes to interindividual
comparisons. As stabilized pH values for >10 min
is a criterion for manually determining the phys-
iological landmarks, and the capsule has a negli-
gible lag phase for detecting pH changes, 15-min
measurements are likely sufficient [60]. Neverthe-
less, we support further validation studies to estab-
lish a consensus. Lastly, to investigate the asso-
ciation between diabetic diarrhoea and autonomic
dysfunction, we measured heart rate variability,
baroreflex sensitivity and orthostatic hypotension
[28]. These are validated methods for assessing
cardiac autonomic function and often used as a
proxy for visceral autonomic neuropathy due to the
lack of ideal tests for evaluating gastrointestinal
autonomic function [27,62]. We have previously
demonstrated an association between impaired
rectal sensitivity, indicating autonomic neuropa-
thy, and reduced cardiac autonomic function [40].
Others have also found an association between car-
diac autonomic neuropathy and gastric vagal neu-
ropathy [63].
Our study had some limitations. Being an
exploratory study, we did not perform an a pri-
ori power analysis, but our main findings still had
moderate effect sizes. However, our studymay have
been underpowered to identify a minor difference
in small bowel transit. We also included patients
having comorbidities or using drugs associated
with diarrhoea (Table S1). Due to their frequency,
excluding these patients would potentially intro-
duce a selection bias. To assess eventual influence
from comorbidities, we compared GSRS scores,
only finding a marginally lower free thyroxine in
diarrhoea patients (Table S1). Since the difference
between groups was within the biological varia-
tion of free thyroxine, and both groups were in an
euthyroid state, we find this unlikely to have had
an influence on symptoms [64]. As for medications,
we found higher diarrhoea scores in patients using
opioids and antiepileptic drugs, both drug classes
common in the treatment of painful neuropathy.
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Considering this, we find it unlikely that our main
findings could be explained by medications.
The main strength of our study was the use of
state-of-the-art technology to assess gastrointesti-
nal motility, pH levels and autonomic function.
To our knowledge, this is the largest experimen-
tal study to date investigating diabetic diarrhoea.
Whilst similar studies often have a retrospective
design, we used prospective inclusion. Thereby we
limited potential biases and were able to stan-
dardize patient characterization using structured
interviews, review of medicine lists and measure-
ment of biochemical parameters. Another strength
was the measurement of faecal calprotectin and
faecal elastase-1 to exclude previously undiag-
nosed inflammatory bowel disease and pancreatic
exocrine insufficiency, respectively.
To conclude, we found that patients with dia-
betic diarrhoea had slower gastric emptying, faster
colonic transit and altered gastrointestinal pH lev-
els. Overall, our findings do not support the asso-
ciation between diabetic diarrhoea and autonomic
dysfunction. Our results add increased knowledge
to a field largely devoid of research for the last two
decades. Hopefully, they provide the groundwork
for further studies into the pathophysiology of dia-
betic diarrhoea. Our study also proves that mea-
surement of transit times and intestinal pH levels
can be a valuable guide for individualized treat-
ment and may warrant a more central role in the
evaluation of diabetic diarrhoea.
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